Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Mineralys Therapeutics, Inc. (MLYS) had Consolidated Net Income/Loss of $-39.34M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-39.34M |
|
-- |
|
-- |
|
$45.34M |
|
$-45.34M |
|
$6.00M |
|
$-39.34M |
|
$-39.34M |
|
$-39.34M |
|
$-39.34M |
|
|
Consolidated Net Income/Loss |
$-39.34M |
$-39.34M |
|
$-45.34M |
|
$-45.33M |
|
82.83M |
|
82.83M |
|
$-0.47 |
|
$-0.47 |
|
| Balance Sheet Financials | |
$652.47M |
|
$0.03M |
|
$0.39M |
|
$652.86M |
|
$14.72M |
|
-- |
|
-- |
|
$14.72M |
|
$638.14M |
|
$638.14M |
|
$638.14M |
|
82.45M |
|
| Cash Flow Statement Financials | |
$-39.47M |
|
$-44.94M |
|
$24.27M |
|
$172.92M |
|
$112.78M |
|
$-60.14M |
|
$6.55M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
44.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-39.47M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.16% |
|
-6.16% |
|
-6.03% |
|
-6.16% |
|
$7.74 |
|
$-0.48 |
|
$-0.48 |
|